Sensitivity toward sorafenib and sunitinib varies between different activating and drug-resistant FLT3-ITD mutations

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Activating mutations in FMS-like tyrosine kinase 3 (FLT3) are common in acute myeloid leukemia (AML).
• FLT3 inhibitors are a promising therapeutic strategy, but resistance frequently emerges.
• Characterizing inhibitor activity against various FLT3 mutations is crucial for treatment development.

Purpose of the Study:

• To evaluate the efficacy of sunitinib and sorafenib against primary FLT3 activating mutations (internal tandem duplication [ITD] and D835Y).
• To assess the activity of these inhibitors against secondary FLT3 resistance mutations.
• To establish sensitivity profiles for sunitinib and sorafenib in the context of FLT3 mutations.

Main Methods:

• Ba/F3 cell lines expressing oncogenic FLT3 mutations were utilized.
• Cell proliferation assays determined half-maximal inhibitory concentrations (IC50) for sunitinib and sorafenib.
• Western blotting confirmed differential IC50 values, and flow cytometry measured cell death.

Main Results:

• Sorafenib demonstrated greater potency against FLT3-ITD than FLT3-D835Y.
• Sunitinib showed equal effectiveness against both FLT3-ITD and FLT3-D835Y mutations.
• Sensitivity to both sunitinib and sorafenib varied significantly among different secondary FLT3-ITD resistance mutations.

Conclusions:

• The study established distinct sensitivity profiles for sunitinib and sorafenib against various FLT3 mutations.
• These findings can inform the development of rational treatment strategies for AML patients.
• Understanding inhibitor sensitivity is vital for overcoming resistance in FLT3-mutated AML.